MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors

Abramovich, Caroline M.; Prayson, Richard A.

doi:10.1016/s0046-8177(98)90010-7

Cited by 82 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other proliferative cells like lymphocytes can also show positivity for MIB1 LI, and a meticulous comparison with H and E stain would help to eliminate this error [20,21].…”

Section: Resultsmentioning

confidence: 99%

The Study of MIB -1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma

Bohra

Rathi

Dudani

et al. 2016

JCDR

View full text Add to dashboard Cite

“…Other proliferative cells like lymphocytes can also show positivity for MIB1 LI, and a meticulous comparison with H and E stain would help to eliminate this error [20,21].…”

Section: Resultsmentioning

confidence: 99%

The Study of MIB -1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma

Bohra

Rathi

Dudani

et al. 2016

JCDR

View full text Add to dashboard Cite

“…2). Other reports demonstrated that the mean MIB-1 SI of nonrecurrent meningiomas ranged from 0.98 to 3.8%, whereas that of recurrent meningiomas ranged from 4.0 to 8.8% [1,28,32,44]. A recent report by Roser et al also found that MIB-1 SI is significantly correlated with WHO grading of meningioma [49].…”

Section: ) Mib-1 Si and Histopathological Subtypes Of Meningiomasmentioning

confidence: 90%

“…The representative MIB-1 immunohistochemical stainings are shown in Figure 1. Other several reports have conducted that the mean MIB-1 SI for benign meningiomas ranged from 0.7 to 2.2%, that for atypical meningiomas ranged from 2.1 to 9.3%, and that for anaplastic meningiomas ranged from 11.0 to 16.3% [1,26,28,43]. Perry et al described that MIB-1 SI appears to be of greatest value in the evaluation of tumors exhibiting borderline atypia [47].…”

Section: ) Mib-1 Si and Histopathological Subtypes Of Meningiomasmentioning

confidence: 97%

Histopathological Analyses of Proliferative Potentials of Intracranial Meningiomas Using Bromodeoxyuridine and MIB-1 Immunohistochemistry

Matsuno

Nakaguchi

Nagashima

et al. 2005

Acta Histochem. Cytochem

View full text Add to dashboard Cite

The proliferative potentials of intracranial meningiomas, as represented by bromodeoxyuridine (BrdU) labeling index (LI) and MIB-1 staining index (SI), were examined, and their correlation with recurrence and regrowth of meningiomas was reviewed. The mean BrdU LI of recurrent meningiomas was reported to be significantly higher than that of nonrecurrent meningiomas. BrdU LI can predict the time to re-operation. Many studies have been conducted to examine the relationship between MIB-1 SI and clinical outcome of meningiomas, and most of them showed a significant relationship. Time interval to next recurrence in recurrent meningiomas is associated with MIB-1 SI, and several investigators have shown a cut-off point for MIB-1 SI that can predict future recurrence. BrdU LI, MIB-1 SI, and tumor doubling time of intracranial meningiomas have a mutual relationship. While many other biological or genetic variables can affect the proliferation of tumors, nevertheless BrdU LI and MIB-1 SI are closely correlated with clinical recurrence or regrowth of meningiomas.

show abstract

“…A number of previous studies have found that the Ki-67 labeling index is associated with meningioma grade and possibly with the risk of recurrence, whereas others have failed to identify such a correlation (29)(30)(31). In WHO grade I meningiomas, a Ki-67 labeling index of >4% may portend relapse (29).…”

Section: Discussionmentioning

confidence: 99%

STAT3 activation and risk of recurrence in meningiomas

2017

View full text Add to dashboard Cite

Abstract. Several studies have suggested that activation of signal transducer and activator of transcription 3 (STAT3) is associated with initiation, progression and metastasis of numerous types of malignancy. However, the role of the Janus kinase-interleukin 6-STAT3 signaling pathway in the pathogenesis and recurrence of meningiomas is unknown. The present study evaluated STAT3 activation by western blotting and immunohistochemistry and assessed its association with Ki-67 labeling in 13 cases of meningioma in which frozen tissue and ≥5.5-year follow-up information were available, and in formalin-fixed meningioma tissues from 14 cases with an 8.4-year follow-up. The results of the western blot analysis indicated that STAT3 phosphorylation was markedly higher in grade II meningiomas compared with that in grade I, with mean densitometric values of 8.6 and 1.7 following normalization to actin, respectively. High STAT3 phosphorylation/activation was identified in 2 of 3 recurrent World Health Organization (WHO) grade I meningiomas and 0 of 3 non-recurrent meningiomas. Strong STAT3 phosphorylation/activation signal was also found in 2 of 4 recurrent grade II meningiomas and 1 of 3 non-recurrent cases. According to the immunohistochemistry results, phospho-STAT3 was not increased in WHO grade II tumors compared with that in grade I tumors, and was not significantly different between recurrent and non-recurrent cases. Ki-67 labeling was significantly increased in grade II vs. grade I tumors, and was also significantly increased in recurrent compared with non-recurrent grade I meningiomas. The results of the current study suggest that, while detection of phosphorylated/activated STAT3 may be useful in isolated cases, identifying activation may be of little value in predicting recurrence.

show abstract

MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors

Cited by 82 publications

References 31 publications

The Study of MIB -1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma

The Study of MIB -1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma

Histopathological Analyses of Proliferative Potentials of Intracranial Meningiomas Using Bromodeoxyuridine and MIB-1 Immunohistochemistry

STAT3 activation and risk of recurrence in meningiomas

Contact Info

Product

Resources

About